Sex: F
Vaccine: COVID19
Symptoms: Protein total, Red blood cell count, SARS-CoV-2 test, Visual acuity tests, Visual field tests
Clinical narrative: PCR tests for SARS-CoV-2 were positive in both the patient and her son; PCR tests for SARS-CoV-2 were positive in both the patient and her son; This is a literature report for the following literature source(s):   A 44-year-old female patient received BNT162b2 (BNT162B2), in Mar2021 as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "psoriasis" (unspecified if ongoing); "dyschromatopsia" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "PCR tests for SARS-CoV-2 were positive in both the patient and her son". The patient underwent the following laboratory tests and procedures: Angiogram retina: (unspecified date) revealed only optic disc leakage OS, and photos, notes: documented resolution of heme and cotton wool 3 days later; Anti-aquaporin-4 antibody: (unspecified date) negative; Antibody test: (unspecified date) negative; Blood glucose: (unspecified date) 66; Colour vision tests: (unspecified date) 8/8, notes: OU with mild red desaturation OS; Computerised tomogram thorax: (unspecified date) did not reveal evidence of sarcoid; CSF oligoclonal band: (unspecified date) Negative; Fundoscopy: (unspecified date) Initial disc edema and hyperemia OS; (unspecified date) otherwise-normal, notes: and mild, 270-degree disc edema with hyperemia OS; Lumbar puncture: (unspecified date) 0 WBC, 36 RBC, notes: protein 23, glucose 66, and negative oligoclonal bands Bland; Magnetic resonance imaging: (unspecified date) revealed enhancement of the, notes: intraorbital left optic nerve sparing the optic nerve sheath and orbital fat stranding; Magnetic resonance imaging head: (unspecified date) normal; Magnetic resonance imaging spinal: (unspecified date) Normal; Ophthalmological examination: (unspecified date) Her optic disc appearance normalized, notes: within 6 weeks; (unspecified date) revealed rAPD and dyschromatopsia OS; (unspecified date) evealed stable afferent visual function, worsened, notes: disc edema, and recurrent obscuration of a single vessel at the nasal disc with several new small foci of peripapillary heme; (unspecified date) normal; Protein total: (unspecified date) 23; Red blood cell count: (unspecified date) 36; SARS-CoV-2 test: (unspecified date) Positive; Visual acuity tests: (unspecified date) 20/30, notes: Initial examination right eye; (unspecified date) 20/50, notes: left eye; (unspecified date) 20/20, notes: right eye; (unspecified date) 20/25, notes: left eye; (unspecified date) 20/20, notes: improved left eye. Final Acuity 20/20, 20/20; (Jul2021) red desaturation remained mild, and disc edema, notes: remained stable; (Jul2021) Unknown result; Visual field tests: (unspecified date) patchy loss OS and a rAPD OS; (unspecified date) Patchy, nonspecific defects with mildly reduced, notes: total sensitivity; White blood cell count: (unspecified date) 0.  No follow-up attempts are possible.; Sender's Comments: Based on the known information available the Causal relation between the events Drug ineffective, Covid 19 and suspect drug cannot be excluded completely,Linked Report(s) : US-PFIZER INC-PV202300205493 Same article/drug/event different patient.;